Trial Profile

An open-label, Randomized, Phase 3 Registrational bridging study of 177Lu PSMA I&T comparing with Hormone Therapy in Chinese Patients with Metastatic Castration-Resistant Prostate Cancer

Status: Planning

Phase of Trial: Phase III

Latest Information Update: 27 Jan 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

27 Jan 2026 New trial record
07 Jan 2026 According to a Curium Pharma media release, the Center for Drug Evaluation (CDE) China has accepted the company's IND for this trial and it is now under review. The study will serve as a registrational trial in China and will leverage data from Curium's ongoing global clinical trial.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com